We act as a trusted partner to transform the way rare diseases are identified and treated.
Dr Ian Gilham appointed new Chair of Trustees to succeed Dr John Stageman when he steps down on 4 April after eight years.
A research study looking into a new approach to treat primary sclerosing cholangitis (PSC) is progressing to clinical trials.
Today is the UN’s International Day of Women and Girls in Science and we are delighted to have…
Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO). Dave is an experienced scientist and leader, with…
As we bid farewell to another challenging year, we reflect on our work with partners and colleagues in 2021.
Richard Godfrey has joined LifeArc as its first Chief Operating Officer (COO). The new role will strengthen…
LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.